Video

Dr. Rotow on Results of a Phase 1/2 Trial With Osimertinib/Gefitinib in EGFR-Mutant NSCLC

Julia K. Rotow, MD, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib in combination with gefitinib as a first-line treatment for patients with stage IV EGFR-mutant non–small cell lung cancer.

Julia K. Rotow, MD, medical oncologist, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, discusses the results of an ongoing phase 1/2 trial evaluating the safety and efficacy of osimertinib (Tagrisso) in combination with gefitinib (Iressa) as a first-line treatment for patients with stage IV EGFR-mutant non—small cell lung cancer (NSCLC).

The dose-escalation phase of this study confirmed that 80 mg of osimertinib plus 250 mg of gefitinib once daily was the maximum-tolerated dose, says Rotow.

Although the trial is ongoing, initial safety findings suggest that the combination is well tolerated, says Rotow. A feasibility analysis demonstrated that 81.5% of patients completed at least 6 cycles of combination therapy.

The overall response rate was 85.2% (95% CI, 67.5-94.1), with 14.8% of patients experiencing stable disease. These findings are comparable with osimertinib monotherapy; however, these data are not fully matured as enrollment is ongoing, explains Rotow.

Once the data have fully matured, progression-free survival will be an important end point to evaluate as it may determine whether the potential clinical benefit of the combination regimen outweighs the added toxicity, concludes Rotow.

Related Videos
John L. Marshall, MD
Petros Grivas, MD, PhD
Noopur S. Raje, MD
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA
Atish D. Choudhury, MD, PhD
Benjamin Levy, MD
Paolo Tarantino, MD
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Sujith Samarasinghe, MD
Suzanne Trudel, MSc, MD